Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
---|---|---|---|---|---|---|
2016 | Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: Post hoc analyses of the randomized LUX-Lung 3 and 6 trials | CHIH-HSIN YANG ; Sequist L.V; Zhou C; Schuler M; Geater S.L; Mok T; Hu C.-P; Yamamoto N; Feng J; O'Byrne K; Lu S; Hirsh V; Huang Y; Sebastian M; Okamoto I; Dickgreber N; Shah R; Märten A; Massey D; Wind S; Wu Y.-L. | Annals of Oncology | 152 | 142 |